These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 22652313)
1. Too early to call. Waksman R Cardiovasc Revasc Med; 2012; 13(3):157-8. PubMed ID: 22652313 [No Abstract] [Full Text] [Related]
2. PCI in small vessels: the case for a drug-coated balloon based intervention. Zeymer U; Scheller B EuroIntervention; 2011 May; 7 Suppl K():K57-60. PubMed ID: 22027729 [No Abstract] [Full Text] [Related]
3. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925 [TBL] [Abstract][Full Text] [Related]
5. Percutaneous UPLM revascularisation: the time has come. Goyal BK Catheter Cardiovasc Interv; 2010 Jun; 75(7):1050. PubMed ID: 20517967 [No Abstract] [Full Text] [Related]
6. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo. Belardi J Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848 [No Abstract] [Full Text] [Related]
8. If I've heard it once, I've heard it (not yet) a hundred times. Butman SM Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224 [No Abstract] [Full Text] [Related]
9. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods. Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737 [TBL] [Abstract][Full Text] [Related]
10. Another small step for small vessels. Morrison DA Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195 [No Abstract] [Full Text] [Related]
11. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. Tcheng JE; Zidar DA JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554 [No Abstract] [Full Text] [Related]
12. Do we really understand pimecrolimus? Vorpahl M; Finn AV; Nakano M; Virmani R JACC Cardiovasc Interv; 2009 Oct; 2(10):1025-7. PubMed ID: 19850265 [No Abstract] [Full Text] [Related]
13. Drug-eluting stent implantation for the treatment of cardiac transplant vasculopathy: the jury is still out. Belardi JA Catheter Cardiovasc Interv; 2011 Jun; 77(7):970-1. PubMed ID: 21598349 [No Abstract] [Full Text] [Related]
14. From TAVI to TAVR: transforming imagination into reality. Waksman R Cardiovasc Revasc Med; 2011; 12(6):343-4. PubMed ID: 22078640 [No Abstract] [Full Text] [Related]
15. Delayed subtotal coronary obstruction after transapical aortic valve implantation. Kukucka M; Pasic M; Dreysse S; Hetzer R Interact Cardiovasc Thorac Surg; 2011 Jan; 12(1):57-60. PubMed ID: 21098421 [TBL] [Abstract][Full Text] [Related]
17. NEVO™: a new generation of sirolimus-eluting coronary stent. Falotico R; Parker T; Grishaber R; Price S; Cohen SA; Rogers C EuroIntervention; 2009 Dec; 5 Suppl F():F88-93. PubMed ID: 22100684 [No Abstract] [Full Text] [Related]
18. Assimilating the current clinical data of fully bioabsorbable stents. Di Mario C; Borgia F EuroIntervention; 2009 Dec; 5 Suppl F():F103-8. PubMed ID: 22100669 [No Abstract] [Full Text] [Related]